BFM
CRSP icon

Boothbay Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

Boothbay Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-40,800
Closed -$2.29M – 1793
2023
Q2 		$2.29M Buy
+40,800
New +$2.32M 0.05% 506

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's CRSP Position: Q1 2024 in Review

Boothbay Fund Management sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 18,269 shares — an estimated $1.14M sold.

Boothbay Fund Management first reported a position in CRSP in Q2 2019 and held it in 6 quarters. The position peaked at $2.21M in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Boothbay Fund Management reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 18,269 CRISPR Therapeutics shares in Q1 2024, an estimated $1.14M.
  • Boothbay Fund Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 6 quarters.
  • Boothbay Fund Management's CRISPR Therapeutics position peaked at $2.21M in Q2 2021.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.